Covaxin Phase 3 Data Shows 77.8% Efficacy, Says Lancet

PUBLISHED ON: November 12, 2021 | Duration: 2 min, 58 sec

facebooktwitteremailkoo
loading..
Covaxin, the coronavirus vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 per cent efficacy rate against symptomatic COVID-19 in a long-awaited analysis published in The Lancet. The study also found it to be 65.2 per cent effective against the more dangerous Delta variant of the coronavirus in its preliminary analysis but said further investigations are necessary to confirm it.
ALSO WATCH
"एक और महामारी के लिए भारत से बेहतर कोई राष्ट्र तैयार नहीं" : अदार पूनावाला

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com